ADC Therapeutics is a biotechnology business based in the US. ADC Therapeutics shares (ADCT) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was $1.94 – a decrease of 18.83% over the previous week. ADC Therapeutics employs 273 staff and has a trailing 12-month revenue of around $70.7 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $1.94 |
|---|---|
| 52-week range | $0.68 - $6.04 |
| 50-day moving average | $3.03 |
| 200-day moving average | $3.66 |
| Wall St. target price | $8.40 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-2.39 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.98 from 2024-11-20
| 1 week (2024-11-14) | -25.28% |
|---|---|
| 1 month (2024-10-21) | -36.54% |
| 3 months (2024-08-21) | -32.65% |
| 6 months (2024-05-21) | -46.92% |
| 1 year (2023-11-21) | 173.48% |
|---|---|
| 2 years (2022-11-21) | -47.48% |
| 3 years (2021-11-19) | 22.84 |
| 5 years (2019-11-18) | N/A |
| Revenue TTM | $70.7 million |
|---|---|
| Gross profit TTM | $35.1 million |
| Return on assets TTM | -21.17% |
| Return on equity TTM | -705.53% |
| Profit margin | -300% |
| Book value | $-1.78 |
| Market Capitalization | $256.2 million |
TTM: trailing 12 months
We're not expecting ADC Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, ADC Therapeutics's shares have ranged in value from as little as $0.684 up to $6.04. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while ADC Therapeutics's is 1.602. This would suggest that ADC Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U. S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets.
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.